[go: up one dir, main page]

DK1527179T3 - IL-7-lægemiddelsubstans, IL-7-holdig sammensætning, fremstilling og anvendelser deraf - Google Patents

IL-7-lægemiddelsubstans, IL-7-holdig sammensætning, fremstilling og anvendelser deraf

Info

Publication number
DK1527179T3
DK1527179T3 DK03792262.2T DK03792262T DK1527179T3 DK 1527179 T3 DK1527179 T3 DK 1527179T3 DK 03792262 T DK03792262 T DK 03792262T DK 1527179 T3 DK1527179 T3 DK 1527179T3
Authority
DK
Denmark
Prior art keywords
drug substance
drug
product
preparation
well
Prior art date
Application number
DK03792262.2T
Other languages
English (en)
Inventor
Michel Christian Morre
Brigitte Assouline
Pierre Cortez
Anne Gregoire
Original Assignee
Cytheris
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytheris filed Critical Cytheris
Application granted granted Critical
Publication of DK1527179T3 publication Critical patent/DK1527179T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5418—IL-7
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK03792262.2T 2002-08-08 2003-08-06 IL-7-lægemiddelsubstans, IL-7-holdig sammensætning, fremstilling og anvendelser deraf DK1527179T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02291996A EP1391513A1 (en) 2002-08-08 2002-08-08 IL-7 drug substance, IL-7 comprising composition, preparation and uses thereof
US47588103P 2003-06-05 2003-06-05
PCT/EP2003/008701 WO2004018681A2 (en) 2002-08-08 2003-08-06 Il-7 drug substance, il- 7 comprising composition, preparation and uses thereof

Publications (1)

Publication Number Publication Date
DK1527179T3 true DK1527179T3 (da) 2011-01-03

Family

ID=30775891

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03792262.2T DK1527179T3 (da) 2002-08-08 2003-08-06 IL-7-lægemiddelsubstans, IL-7-holdig sammensætning, fremstilling og anvendelser deraf

Country Status (17)

Country Link
US (1) US7585947B2 (da)
EP (2) EP1391513A1 (da)
JP (3) JP2005534339A (da)
AT (1) ATE482273T1 (da)
AU (1) AU2003250216B2 (da)
CA (1) CA2494974C (da)
CY (1) CY1110994T1 (da)
DE (1) DE60334301D1 (da)
DK (1) DK1527179T3 (da)
ES (1) ES2353006T3 (da)
IL (1) IL166543A (da)
NO (1) NO332305B1 (da)
PL (1) PL213710B1 (da)
PT (1) PT1527179E (da)
SI (1) SI1527179T1 (da)
WO (1) WO2004018681A2 (da)
ZA (1) ZA200501914B (da)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2367891T3 (es) 2000-09-29 2011-11-10 Schering Corporation Interleucina-10 pegilada.
CA2487673C (en) * 2003-12-02 2010-11-02 F. Hoffmann-La Roche Ag Improved method for the recombinant production and purification of protein kinases
BRPI0418286A (pt) 2003-12-30 2007-05-02 Merck Patent Gmbh proteìnas de fusão de il-7
EP1746161A1 (en) 2005-07-20 2007-01-24 Cytheris Glycosylated IL-7, preparation and uses
CA2619989C (en) * 2005-08-23 2014-06-17 National Research Council Of Canada Regulation of heterologous recombinant protein expression in methylotrophic and methanotrophic bacteria
EP2032695B1 (en) 2006-05-31 2018-08-15 The Regents of The University of California Cd127 expression inversely correlates with foxp3 and suppressive function of cd4+ tregs
US20080081031A1 (en) 2006-09-28 2008-04-03 Schering Corporation Use of Pegylated IL-10 to Treat Cancer
US9266937B2 (en) 2010-12-10 2016-02-23 University Of Central Florida Research Foundation, Inc. Compositions comprising IL-7 receptor ligands
MX2014001355A (es) 2011-08-03 2014-11-21 Cytheris Inmunoterapia contra el vhc.
JP6126684B2 (ja) * 2012-04-23 2017-05-10 バハラ バイオテック インターナショナル リミテッド 新規なロタウイルスワクチン組成物及び同組成物を調製する方法
RU2562169C2 (ru) * 2012-10-29 2015-09-10 Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства Штамм культивируемых клеток cho-il7/13 - продуцент интерлейкина-7 человека
CA2908198A1 (en) 2013-04-18 2014-10-23 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
EP3434277A1 (en) 2013-06-17 2019-01-30 Armo Biosciences, Inc. Method for assessing protein identity and stability
RU2016122957A (ru) 2013-11-11 2017-12-19 Армо Байосайенсиз, Инк. Способы применения интерлейкина-10 для лечения заболеваний и расстройств
US20180028593A1 (en) 2014-03-21 2018-02-01 Boreal Invest Terminal nanofiltration of solubilized protein compositions for removal of immunogenic aggregates
CN106573072A (zh) 2014-06-02 2017-04-19 阿尔莫生物科技股份有限公司 降低血清胆固醇的方法
CN107106655A (zh) 2014-10-22 2017-08-29 阿尔莫生物科技股份有限公司 使用白细胞介素‑10治疗疾病和病症的方法
WO2016126615A1 (en) 2015-02-03 2016-08-11 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
IL254389B2 (en) * 2015-03-11 2023-03-01 Nektar Therapeutics Polymer conjugates and the il–7 group
KR20180020141A (ko) 2015-05-28 2018-02-27 아르모 바이오사이언시스 인코포레이티드 암 치료에 사용되는 peg화된 인터류킨-10
EP3307766A4 (en) * 2015-06-11 2019-06-12 Genexine, Inc. MODIFIED INTERLEUKIN-7 PROTEIN AND USES THEREOF
KR102386735B1 (ko) * 2015-11-06 2022-04-14 주식회사 제넥신 변형된 인터루킨-7 융합 단백질의 제형
RU2615447C1 (ru) * 2015-11-13 2017-04-04 Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства Синтетическая ДНК, кодирующая интерлейкин-7 человека, содержащий ее экспрессионный вектор (варианты), штамм-продуцент интерлейкина-7 человека и способ получения интерлейкина-7 человека
CN108697765A (zh) * 2015-12-04 2018-10-23 格纳西尼有限公司 用于预防或治疗人乳头瘤病毒引起的疾病的含有免疫球蛋白fc融合il-7融合蛋白的药物组合物
KR102604595B1 (ko) * 2015-12-04 2023-11-21 주식회사 제넥신 면역글로불린 Fc가 융합된 인터루킨-7 융합 단백질을 포함하는 인플루엔자 바이러스 감염의 예방 또는 치료용 약학적 조성물
WO2018156649A1 (en) * 2017-02-22 2018-08-30 Flagship Pioneering, Inc. Compositions of t cell modulator (tcm) molecules and uses thereof
WO2020102728A1 (en) 2018-11-16 2020-05-22 Neoimmunetech, Inc. Method of treating a tumor with a combination of il-7 protein and an immune checkpoint inhibitor
CA3123338A1 (en) 2018-12-21 2020-06-25 Ose Immunotherapeutics Bifunctional anti-pd-1/il-7 molecule
KR102402276B1 (ko) * 2019-11-15 2022-05-26 주식회사 제넥신 변형된 인터루킨-7 및 tgf 베타 수용체 ii를 포함하는 융합단백질 및 이의 용도
JP2023512456A (ja) 2020-01-13 2023-03-27 ネオイミューンテック， インコーポレイテッド Ｉｌ－７タンパク質と二重特異性抗体の組み合わせで腫瘍を治療する方法
JP2023512657A (ja) 2020-02-05 2023-03-28 ワシントン・ユニバーシティ Ｉｌ－７タンパク質とｃａｒ保有免疫細胞の組み合わせで固形腫瘍を治療する方法
EP4232070A1 (en) 2020-10-26 2023-08-30 NeoImmuneTech, Inc. Methods of inducing stem cell mobilization
EP4236989A1 (en) 2020-11-02 2023-09-06 NeoImmuneTech, Inc. Use of interleukin-7 for the treatment of coronavirus
US20240115675A1 (en) 2020-11-05 2024-04-11 Neoimmunetech, Inc. Method of treating a tumor with a combination of an il-7 protein and a nucleotide vaccine
US20240092851A1 (en) * 2020-11-25 2024-03-21 Jecho Laboratories, Inc. Il-7 fusion protein and related methods
WO2022117569A1 (en) 2020-12-02 2022-06-09 Oncurious Nv A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
JP2025501238A (ja) 2021-12-30 2025-01-17 ネオイミューンテック， インコーポレイテッド Ｉｌ－７タンパク質とｖｅｇｆアンタゴニストの併用による腫瘍の治療方法
EP4463135A2 (en) 2022-01-10 2024-11-20 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023193015A1 (en) 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
WO2024102722A1 (en) 2022-11-07 2024-05-16 Neoimmunetech, Inc. Methods of treating a tumor with an unmethylated mgmt promoter
CN117050178B (zh) * 2023-10-13 2024-01-12 北京百普赛斯生物科技股份有限公司 特异性检测il-7的抗体及应用
WO2025093541A1 (en) 2023-10-31 2025-05-08 Ose Immunotherapeutics Combination of interleukin 7 and tumour associated antigen vaccine

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4965195A (en) * 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US5328988A (en) * 1987-10-26 1994-07-12 Immunex Corporation Interleukin-7
ZA887773B (en) * 1987-10-26 1989-07-26 Immunex Corp Interleukin-7
US5714585A (en) * 1987-10-26 1998-02-03 Sterling Winthrop, Inc. Antibodies that are immunoreactive with interleukin-7
US5728680A (en) * 1987-12-30 1998-03-17 Cytoven J.V. Methods for normalizing numbers of lymphocytes
US5459058A (en) * 1991-03-28 1995-10-17 Benjamin Rich Cell culture system
US5223408A (en) * 1991-07-11 1993-06-29 Genentech, Inc. Method for making variant secreted proteins with altered properties
WO1994022473A1 (en) * 1993-04-01 1994-10-13 University Of Washington Use of interleukin 7 to improve vaccine potency
US5696234A (en) * 1994-08-01 1997-12-09 Schering Corporation Muteins of mammalian cytokine interleukin-13
DE69838552T2 (de) * 1997-07-14 2008-05-21 Bolder Biotechnology, Inc., Louisville Derivate des wachstumshormons und verwandte proteine
EP2314696A1 (en) * 1998-09-21 2011-04-27 Schering Corporation Therapeutic uses of human Interleukin-B50 antagonist.
CA2404479A1 (en) * 2000-03-30 2001-10-11 University Of Connecticut Hybrid cytokine of il-7 and .beta.-chain of hepatocyte growth factor
BRPI0418286A (pt) 2003-12-30 2007-05-02 Merck Patent Gmbh proteìnas de fusão de il-7
EP1746161A1 (en) 2005-07-20 2007-01-24 Cytheris Glycosylated IL-7, preparation and uses

Also Published As

Publication number Publication date
CA2494974C (en) 2014-07-29
CA2494974A1 (en) 2004-03-04
PL373606A1 (en) 2005-09-05
ZA200501914B (en) 2005-11-30
US7585947B2 (en) 2009-09-08
ATE482273T1 (de) 2010-10-15
JP5980467B2 (ja) 2016-08-31
IL166543A (en) 2012-02-29
EP1391513A1 (en) 2004-02-25
NO332305B1 (no) 2012-08-20
AU2003250216B2 (en) 2010-08-05
ES2353006T3 (es) 2011-02-24
JP2005534339A (ja) 2005-11-17
JP2014147396A (ja) 2014-08-21
HK1075465A1 (en) 2005-12-16
AU2003250216A1 (en) 2004-03-11
PL213710B1 (pl) 2013-04-30
WO2004018681A2 (en) 2004-03-04
US20050249701A1 (en) 2005-11-10
JP2010115203A (ja) 2010-05-27
PT1527179E (pt) 2010-12-07
IL166543A0 (en) 2006-01-15
WO2004018681A3 (en) 2004-04-01
SI1527179T1 (sl) 2011-04-29
EP1527179B1 (en) 2010-09-22
NO20050355L (no) 2005-05-06
DE60334301D1 (de) 2010-11-04
CY1110994T1 (el) 2015-06-11
EP1527179A2 (en) 2005-05-04

Similar Documents

Publication Publication Date Title
DK1527179T3 (da) IL-7-lægemiddelsubstans, IL-7-holdig sammensætning, fremstilling og anvendelser deraf
Van Coillie et al. Functional comparison of two human monocyte chemotactic protein-2 isoforms, role of the amino-terminal pyroglutamic acid and processing by CD26/dipeptidyl peptidase IV
DK2027152T3 (da) Peptidfragmenter til induktion af syntese af ekstracellulære matrixproteiner
DE60125381D1 (de) Zusammensetzungen und verfahren mit analogen von g-csf
NO20054414L (no) Dihydropteridinoner, metoder for deres fremstilling og bruk av disse som medisiner
NO882341L (no) Ekspresjon av humant proapolipoprotein a-i.
CZ283149B6 (cs) Lidský nádorový nekrotický faktor, způsob jeho výroby, DNA kódující lidský nádorový nekrotický faktor, buňka transformovaná touto DNA, prostředek, který obsahuje lidský nádorový nekrotický faktor a prostředek vhodný pro léčení nádorů
DE602004001727D1 (de) Verfahren zur herstellung cyclischer peptide
IL206157A (en) Pancreatic elastase protein of type 1, a nucleic acid molecule encoded by a protein
Jalil et al. Multivalent, soluble nano-self peptides increase phagocytosis of antibody-opsonized targets while suppressing “self” signaling
HRP20050585A2 (en) Peptides which inhibit angiogenesis, cell migration, cell invasion and cell proliferation, compositions and uses thereof
Hao et al. Molecular cloning, recombinant expression and antibacterial activity analysis of hepcidin from Simensis crocodile (Crocodylus siamensis)
EP1252183B1 (en) Method for reducing the immunogenicity of staphylokinase by elimination of t-cell epitopes
MXPA05011595A (es) Composiciones de spex y metodos de uso.
DK1947175T3 (da) Sekvens af nukleotider og peptider GSE 24,2 af dyskerin, der kan fremkalde telomeraseaktivitet, fremgangsmåde til fremstilling deraf, terapeutiske sammensætninger og anvendelser deraf
DE3751646D1 (de) Rekombinantes Produkt
RU2004136170A (ru) Химерный антагонист anth1
CN106478811B (zh) 虎纹蛙蛋白酶抑制肽及其基因和在制药中的应用
GR3031254T3 (en) Novel derivatives of peptides therapeutically active in the cascade sequence for blood coagulation, process for their preparation and pharmaceutical compositions containing same
Musavi Motlagh et al. Improving purification of coagulation F IX using heparin affinity chromatography and its comparison with ion exchange chromatography
AU676842B2 (en) Neutrophil stimulating peptides
Huang et al. Structure-guided synthesis of melittin analogs with reduced hemolysis and enhanced anti-inflammatory activity
Shingarova et al. Novel mutants of human tumor necrosis factor with dominant-negative properties
KR100443570B1 (ko) 재조합 인간 인터루킨-4의 제조방법
UA99481C2 (ru) СПОСОБ ПОЛУЧЕНИЯ РЕКОМБИНАНТНОГО с-ПЕПТИДА ПРОИНСУЛИНА ЧЕЛОВЕКА